Citadel Advisors’s CAS Medical Systems CASM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q2
– Sell
-45,708
Closed -$111K – 10336
2019
Q1
$111K Buy
+45,708
New +$98.3K ﹤0.01% 8511
2018
Q4
– Sell
-10,453
Closed -$24K – 10167
2018
Q3
$24K Buy
+10,453
New +$22.3K ﹤0.01% 8986
2018
Q1
– Sell
-32,680
Closed -$25K – 9095
2017
Q4
$25K Buy
+32,680
New +$23.9K ﹤0.01% 7799
2017
Q3
– Sell
-17,859
Closed -$21K – 8364
2017
Q2
$21K Buy
+17,859
New +$20.4K ﹤0.01% 7280
2017
Q1
– Sell
-18,595
Closed -$30K – 8344
2016
Q4
$30K Buy
+18,595
New +$31.2K ﹤0.01% 6993
2016
Q3
– Sell
-10,236
Closed -$19K – 8031
2016
Q2
$19K Buy
+10,236
New +$19.2K ﹤0.01% 6810
2014
Q1
– Sell
-11,743
Closed -$20K – 8288
2013
Q4
$20K Buy
+11,743
New +$18.3K ﹤0.01% 6465
2013
Q3
– Sell
-13,522
Closed -$22K – 6963
2013
Q2
$22K Hold
13,522
– – ﹤0.01% 6037

Citadel Advisors's CASM Position: Q2 2019 in Review

Citadel Advisors sold out of CAS Medical Systems (CASM) in Q2 2019, closing a stake of 45,708 shares — an estimated $111K sold.

Citadel Advisors first reported a position in CASM in Q2 2013 and held it in 8 quarters. The position peaked at $111K in Q1 2019. 0 funds tracked by Wall St. Rank hold CASM as of Q2 2019.

  • Citadel Advisors reported no remaining CAS Medical Systems position as of Q2 2019 after selling out during the quarter.
  • Citadel Advisors sold 45,708 CAS Medical Systems shares in Q2 2019, an estimated $111K.
  • Citadel Advisors first reported a position in CAS Medical Systems in Q2 2013 and held it in 8 quarters.
  • Citadel Advisors's CAS Medical Systems position peaked at $111K in Q1 2019.
  • 0 funds tracked by Wall St. Rank held CAS Medical Systems as of Q2 2019.

Based on Citadel Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.